Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment

SIMPLE SUMMARY: Several clinical protocols are exploring the anticancer effect of immunotherapy combined to targeted therapy. Indeed, emerging evidence demonstrates that small-molecule targeted inhibitors promote the antitumor immune response. In the case of mechanistic target of rapamycin (mTOR) in...

Descripción completa

Detalles Bibliográficos
Autores principales: el Hage, Alexandre, Dormond, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002586/
https://www.ncbi.nlm.nih.gov/pubmed/33802831
http://dx.doi.org/10.3390/cancers13061359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002586/
https://www.ncbi.nlm.nih.gov/pubmed/33802831
http://dx.doi.org/10.3390/cancers13061359

Ejemplares similares